
KMTS Stock Forecast & Price Target
KMTS Analyst Ratings
Bulls say
Kestra Medical Techs is leveraging innovative technology to provide a non-invasive solution for early detection and prevention of cardiovascular disease. The focus on expanding coverage and investing in R&D allows for potential growth and market penetration. With FDA approval and strong financials, the company has the potential to become a leader in the MedTech industry, but competition and regulatory decisions should be monitored closely.
Bears say
Kestra Medical Techs is a commercial-stage medical device company focused on wearable defibrillators for patients at risk of sudden cardiac arrest. While it is the gold standard for managing patients with persistent high risk, its main competitor, ZOLL, has lower costs and 98% in-network penetration versus Kestra’s low 80% in a typical quarter. With a historically lower gross margin and breakeven EBIT margin, Kestra must focus on cost reduction initiatives and in-network conversions to achieve cash flow breakeven in 2H29.
This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
KMTS Analyst Forecast & Price Prediction
Start investing in KMTS
Order type
Buy in
Order amount
Est. shares
0 shares